Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GTBP 
GT Biopharma Inc (GTBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: GTBP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.48% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.23M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 936672 | Beta 0.57 | 52 Weeks Range 1.72 - 10.66 | Updated Date 04/6/2025 |
52 Weeks Range 1.72 - 10.66 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.39 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate - | Actual -1.6895 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -60.59% | Return on Equity (TTM) -131.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3815468 | Price to Sales(TTM) - |
Enterprise Value -3815468 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.09 | Shares Outstanding 2234330 | Shares Floating 1665289 |
Shares Outstanding 2234330 | Shares Floating 1665289 | ||
Percent Insiders 12.15 | Percent Institutions 67.52 |
Analyst Ratings
Rating 4 | Target Price 11 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GT Biopharma Inc
Company Overview
History and Background
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies based on its TriKEu00ae platform. Founded to address unmet needs in cancer treatment, the company is pioneering novel approaches to harness the power of the immune system to target and eliminate cancer cells.
Core Business Areas
- TriKEu00ae Platform: GT Biopharma's core business revolves around its TriKEu00ae (Tri-specific Killer Engager) platform. This technology engineers immune cells to target and kill cancer cells.
- Clinical Development: The company focuses on advancing its TriKEu00ae-based drug candidates through clinical trials, primarily targeting hematologic malignancies.
Leadership and Structure
The leadership team comprises experienced professionals in the biopharmaceutical industry, with a focus on drug development and commercialization. The company structure includes research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- GTB-3550 TriKEu00ae: GTB-3550 is a TriKEu00ae-based drug candidate targeting CD33+ hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As a clinical-stage product, it does not currently generate revenue. Competitors include companies developing other immunotherapies for AML, such as antibody-drug conjugates (ADCs) and CAR-T therapies.
- GTB-4550 TriKEu00ae: GTB-4550 is a TriKEu00ae based drug candidate targeting CD33 and CD123. It does not currently generate revenue. Competitors include companies developing other immunotherapies for AML, such as antibody-drug conjugates (ADCs) and CAR-T therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with a strong focus on developing novel cancer therapies. Immunotherapy is a rapidly growing segment, driven by the potential to offer more effective and less toxic treatments compared to traditional chemotherapy.
Positioning
GT Biopharma is positioned as an innovative immunotherapy company with its proprietary TriKEu00ae platform. Its competitive advantage lies in the potential for TriKEu00ae to overcome limitations of existing immunotherapies by engaging a broader range of immune cells and targeting multiple cancer antigens.
Total Addressable Market (TAM)
The total addressable market for hematologic malignancies is substantial, estimated to be in the billions of dollars. GT Biopharma is positioned to capture a portion of this market with its TriKEu00ae platform, focusing initially on AML and MDS.
Upturn SWOT Analysis
Strengths
- Proprietary TriKEu00ae platform
- Potential for broad application across multiple cancer types
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Clinical-stage company with no current revenue
- High reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Risk of competition from established players
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of TriKEu00ae platform to other cancer indications
- Increased adoption of immunotherapy in cancer treatment
Threats
- Failure to achieve positive clinical trial results
- Competition from more established immunotherapy companies
- Changes in regulatory landscape
- Economic downturn impacting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- NK
- AGEN
- TCR2
Competitive Landscape
GT Biopharma faces competition from established immunotherapy companies and companies developing alternative therapies for hematologic malignancies. Its TriKEu00ae platform offers a novel approach, but its success depends on demonstrating clinical efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: GT Biopharma's historical growth is primarily reflected in its clinical development progress and expansion of its TriKEu00ae platform. It has not yet generated significant revenue.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships. Analyst estimates are necessary for specific projections.
Recent Initiatives: Recent initiatives include advancing GTB-3550 through clinical trials, exploring new TriKEu00ae designs, and seeking collaborations with other companies.
Summary
GT Biopharma is a clinical-stage biopharmaceutical company with a promising TriKEu00ae platform for immunotherapy. The company's success hinges on the results of its clinical trials and its ability to secure partnerships. While the technology is innovative, the company faces significant risks associated with drug development and competition. Success will require strong execution and financial resources.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
ALVR
Allovir Inc
ALVR
Allovir Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may not be precise. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GT Biopharma Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2017-09-22 | Interim CEO & Executive Chairman Mr. Michael Martin Breen L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.gtbiopharma.com |
Full time employees 1 | Website https://www.gtbiopharma.com | ||
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 which targets B7-H3 on the surface of advanced solid tumors; GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. GT Biopharma, Inc. entered a master services agreement with Cytovance Biologics, Inc. to perform biologic development and manufacturing services, and to produce and test compounds; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.